“ITM and ILL’s longstanding partnership began in 2009, when the radiopharmaceutical industry was still in its infancy,” commented Dr. Andrew Cavey, CEO of ITM. “Our priority access to ILL’s renowned ...

In the quest for enhanced athletic performance and muscle growth, many fitness enthusiasts and bodybuilders turn to ...

Roche entered into a Licensing, Development, and Commercialisation agreement with Prothena in December 2013 to develop and commercialise monoclonal antibodies targeting aggregated alpha-synuclein, ...

These findings suggest that the combination of olverembatinib and blinatumomab offers promising clinical benefits and an optimal safety profile in patients with Ph+ or Ph-like ALL, thus representing a ...